84 related articles for article (PubMed ID: 3193209)
1. Synthesis of "no-carrier-added" carbon-11 SarCNU: the sarcosinamide analog of the chemotherapeutic agent BCNU.
Conway T; Diksic M
J Nucl Med; 1988 Dec; 29(12):1957-60. PubMed ID: 3193209
[TBL] [Abstract][Full Text] [Related]
2. PET studies of potential chemotherapeutic agents--X. Synthesis of "no-carrier-added" (11C)-HECNU: the hydroxyethyl analog of the chemotherapeutic agent BCNU.
Conway T; Diksic M
Int J Rad Appl Instrum A; 1991; 42(5):441-6. PubMed ID: 1646189
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
Skalski V; Yarosh DB; Batist G; Gros P; Feindel W; Kopriva D; Panasci LC
Mol Pharmacol; 1990 Sep; 38(3):299-305. PubMed ID: 2402223
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Mitsuki S; Diksic M; Conway T; Yamamoto YL; Villemure JG; Feindel W
J Neurooncol; 1991 Feb; 10(1):47-55. PubMed ID: 1902507
[TBL] [Abstract][Full Text] [Related]
5. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC
J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897
[TBL] [Abstract][Full Text] [Related]
6. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
[TBL] [Abstract][Full Text] [Related]
7. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Huynh H; Nguyen TH; Panasci L; Do P
Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
[TBL] [Abstract][Full Text] [Related]
8. The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Skalski V; Feindel W; Panasci LC
J Neurooncol; 1989 Jul; 7(2):189-93. PubMed ID: 2476532
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of "no-carrier-added" alpha-[11C]methyl-L-tryptophan.
Chaly T; Diksic M
J Nucl Med; 1988 Mar; 29(3):370-4. PubMed ID: 3346744
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of "no carrier added" 1,3-bis-(2-chloroethyl)nitrosourea (BCNU).
Diksic M; Farrokhzad S; Yamamoto L; Feindel W
J Nucl Med; 1982 Oct; 23(10):895-8. PubMed ID: 7119883
[No Abstract] [Full Text] [Related]
11. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
Noë AJ; Malapetsa A; Panasci LC
Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272
[TBL] [Abstract][Full Text] [Related]
12. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.
Chen ZP; Remack J; Brent TP; Mohr G; Panasci LC
Clin Cancer Res; 1999 Dec; 5(12):4186-90. PubMed ID: 10632359
[TBL] [Abstract][Full Text] [Related]
13. Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.
Patt M; Solbach C; Wüllner U; Blocher A; Stahlschmidt A; Gündisch D; Kovar KA; Machulla HJ
J Pharm Pharm Sci; 2007; 10(2):312s-320s. PubMed ID: 17718934
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Chen ZP; Wang G; Huang Q; Sun ZF; Zhou LY; Wang AD; Panasci LC
J Neurooncol; 1999 Aug; 44(1):7-14. PubMed ID: 10582663
[TBL] [Abstract][Full Text] [Related]
15. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
Noë AJ; Malapetsa A; Panasci LC
Cancer Res; 1994 Mar; 54(6):1491-6. PubMed ID: 8137253
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity.
Noë AJ; Marcantonio D; Barton J; Malapetsa A; Panasci LC
Biochem Pharmacol; 1996 Jun; 51(12):1639-48. PubMed ID: 8687479
[TBL] [Abstract][Full Text] [Related]
17. The production in high yield of N'-(4-[11C]methyl)-imipramine.
Denutte H; Goethals P; Cattoir H; Bogaert M; Vandewalle T; Vandecasteele C; Jonckheere J; De Leenheer A
J Nucl Med; 1983 Dec; 24(12):1185-7. PubMed ID: 6644379
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
Skalski V; Rivas J; Panasci L; McQuillan A; Feindel W
Cancer Chemother Pharmacol; 1988; 22(2):137-40. PubMed ID: 3409444
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
Plisson C; McConathy J; Martarello L; Malveaux EJ; Camp VM; Williams L; Votaw JR; Goodman MM
J Med Chem; 2004 Feb; 47(5):1122-35. PubMed ID: 14971892
[TBL] [Abstract][Full Text] [Related]
20. [Synthesis of the 14C labelled anticancer agent: N,N-bis(beta-chloroethyl)-N',N"-di(carboethoxy-[14C] methyl)-phosphorotriamide].
Guo JY; Huang L; Tian SH; Zhao QR
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Aug; 6(4):295-7. PubMed ID: 6241072
[No Abstract] [Full Text] [Related]
[Next] [New Search]
